SRT 1720
Modify Date: 2024-01-10 08:31:27
SRT 1720 structure
|
Common Name | SRT 1720 | ||
|---|---|---|---|---|
| CAS Number | 925434-55-5 | Molecular Weight | 469.56100 | |
| Density | 1.46 | Boiling Point | N/A | |
| Molecular Formula | C25H23N7OS | Melting Point | 221ºC | |
| MSDS | N/A | Flash Point | N/A | |
Use of SRT 1720SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities agaiinst SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively. |
| Name | N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide |
|---|---|
| Synonym | More Synonyms |
| Description | SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities agaiinst SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively. |
|---|---|
| Related Catalog | |
| Target |
SIRT1:0.16 μM (EC1.5) SIRT2:37 μM (EC1.5) |
| In Vitro | SRT 1720 effectively decreases the acetylation of p53 in cells even in the absence of SIRT1, and this is attributed to inhibition of histone acetyltransferase p300[2]. |
| In Vivo | SRT 1720 (10, 30, 100 mg/kg, p.o.) significantly reduces the hyperinsulinaemia after 4 weeks, partially normalizing elevated insulin levels similar to rosiglitazone treatment. SRT 1720 treatment significantly reduces fasting blood glucose to near normal levels in Lepob/ob mice[1]. SRT 1720 has ability to protect against the negative effects of diet-induced obesity in mice, and has a connection to metabolic adaptation in fatty acid and oxidative metabolism through downstream targets of SIRT1 such as PGC1α and FOXO1[2]. SRT 1720 (50-100 mg/kg, p.o.), during emphysema development attenuates elastase-induced airspace enlargement and lung function impairment as well as reduces arterial oxygen saturation in WT mice[3]. |
| Animal Admin | Mice: Nine week old C57BL/6 male mice are fed a high fat diet (60% calories from fat) until their mean body weight reach approximately 40 g. The mice are then divided into test groups (6-10 per group). SRT1460 (100 mg/kg), SRT1720 (100 mg/kg), SRT501 (500 mg/kg) and rosiglitazone (5 mg/kg) are administered once daily via oral gavage. The vehicle used is 2% HPMC + 0.2% DOSS. Individual mouse body weights are measured twice weekly. At 2, 4, 6, 8 and 10 weeks of dosing a fed blood glucose measure is taken and after 5 weeks of treatment an IPGTT is conducted on all mice from each of the groups. After 10 weeks of treatment, an ITT is conducted. Statistical analysis is completed using the JMP program. Data are analyzed by a one way ANOVA with comparison to control using a Dunnett’s Test. A p value < 0.05 indicates a significant difference between groups. |
| References |
| Density | 1.46 |
|---|---|
| Melting Point | 221ºC |
| Molecular Formula | C25H23N7OS |
| Molecular Weight | 469.56100 |
| Exact Mass | 469.16800 |
| PSA | 115.69000 |
| LogP | 4.00320 |
| HS Code | 2934100090 |
|---|
|
~%
SRT 1720 CAS#:925434-55-5 |
| Literature: WO2008/156866 A1, ; Page/Page column 74 ; WO 2008/156866 A1 |
|
~%
SRT 1720 CAS#:925434-55-5 |
| Literature: Journal of Medicinal Chemistry, , vol. 52, # 5 p. 1275 - 1283 |
![TERT-BUTYL 4-((6-(2-(QUINOXALINE-2-CARBOXAMIDO)PHENYL)IMIDAZO[2,1-B]THIAZOL-3-YL)METHYL)PIPERAZINE-1-CARBOXYLATE structure](https://www.chemsrc.com/caspic/203/925436-46-0.png)
![N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide 2,2,2-trifluoroacetate structure](https://www.chemsrc.com/caspic/283/1093403-41-8.png)
| Precursor 2 | |
|---|---|
| DownStream 0 | |
| HS Code | 2934100090 |
|---|---|
| Summary | 2934100090 other compounds containing an unfused thiazole ring (whether or not hydrogenated) in the structure VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:20.0% |
| N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide |
| SRT 1720 |